{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:03Z","timestamp":1772119323913,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Mr. Manny and Mrs. Fern Steinfeld","award":["Danny Cunniff Leukemia Research laboratory"],"award-info":[{"award-number":["Danny Cunniff Leukemia Research laboratory"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Unfortunately, cure of multi-drug resistant (MDR) hematologic malignancies remains an unmet need. Donor lymphocyte infusion (DLI) following allogeneic stem cell transplantation (SCT) can sometimes eliminate multi-drug resistant leukemia but at a risk of acute and chronic graft-vs-host disease (GVHD) and procedure-related toxicity. Supported by pre-clinical experiments in animal models, we hypothesized that immunotherapy induced by non-engrafting intentionally mismatched IL-2 activated killers (IMAK) including both T &amp; NK cells could induce safer, faster and much more effective immunotherapy while avoiding the need for SCT and the risks of GVHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      IMAK treatment was applied in 33 patients with MDR hematologic malignancies conditioned with cyclophosphamide 1000\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      based protocol. Haploidentical or unrelated donor lymphocytes were preactivated with IL-2 6000\u00a0IU\/ml for 4\u00a0days. IMAK was combined with Rituximab in 12\/23 patients with CD20\n                      <jats:sup>+<\/jats:sup>\n                      B cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 23\/33 patients with MDR (4 failing SCT) achieved complete remission (CR). First patient currently 30\u00a0years with no further treatment and 6 observed for\u2009&gt;\u20095\u00a0years (2 AML; 2 multiple myeloma, 1 ALL &amp; 1 NHL) can be considered cured. No patient developed\u2009&gt;\u2009grade 3 toxicity or GVHD. No residual male cells were detectable among six females treated with male cells beyond day\u2009+\u20096, confirming that GVHD was prevented by consistent early rejection of donor lymphocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We hypothesize that safe and superior immunotherapy of MDR with cure potential may be accomplished by IMAK, most probably in patients with low tumor burden, but that remains to be confirmed by future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-023-04780-5","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:02:15Z","timestamp":1684447335000},"page":"9277-9284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte"],"prefix":"10.1007","volume":"149","author":[{"given":"Shimon","family":"Slavin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"4780_CR1","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1182\/blood.V78.5.1212.1212","volume":"78","author":"A Ackerstein","year":"1991","unstructured":"Ackerstein A, Kedar E, Slavin S (1991) Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. Blood 78:1212\u20131215","journal-title":"Blood"},{"key":"4780_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu J et al (2022) Natural killer cells: a promising immunotherapy for cancer review. J Transl Med 20:240. https:\/\/doi.org\/10.1186\/s12967-022-03437-0","journal-title":"J Transl Med"},{"key":"4780_CR3","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.4049\/jimmunol.151.9.4803","volume":"151","author":"P Cohen","year":"1993","unstructured":"Cohen P, Vourka-Karussis U, Weiss L et al (1993) Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol 151:4803\u20134810","journal-title":"J Immunol"},{"key":"4780_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"R Collins","year":"1997","unstructured":"Collins R, Shpilberg O, Drobyski W et al (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433\u2013444","journal-title":"J Clin Oncol"},{"key":"4780_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/iji.12387","author":"JK Johnson","year":"2018","unstructured":"Johnson JK, Miller JS (2018) Current strategies exploiting NK-cell therapy to treat hematologic malignancies. Int J Immunogenet. https:\/\/doi.org\/10.1111\/iji.12387","journal-title":"Int J Immunogenet"},{"key":"4780_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1365-3083.2002.01053.x","volume":"55","author":"K K\u00e4rre","year":"2002","unstructured":"K\u00e4rre K (2002) NK cells, MHC class I molecules and the missing self. Scand J Immunol 55:221\u2013228","journal-title":"Scand J Immunol"},{"key":"4780_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041\u20132050","journal-title":"Blood"},{"key":"4780_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","volume":"86","author":"S Mackinnon","year":"1995","unstructured":"Mackinnon S, Papadopoulos EB, Carabasi MH et al (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261\u20131268","journal-title":"Blood"},{"key":"4780_CR9","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood-2005-07-2738","volume":"107","author":"S Morecki","year":"2006","unstructured":"Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S (2006) Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 107:1564\u20131569","journal-title":"Blood"},{"issue":"8","key":"4780_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.exphem.2008.03.005","volume":"36","author":"S Morecki","year":"2008","unstructured":"Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S et al (2008) Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 36(8):997\u20131003","journal-title":"Exp Hematol"},{"key":"4780_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1126\/science.6332379","volume":"225","author":"JJ Mule","year":"1984","unstructured":"Mule JJ, Shu S, Schwarz SL et al (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487\u20131489","journal-title":"Science"},{"key":"4780_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18:85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"key":"4780_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2141.1995.tb08356.x","volume":"89","author":"E Naparstek","year":"1995","unstructured":"Naparstek E, Or R, Nagler A et al (1995) T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor\u2019s peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506\u2013515","journal-title":"Br J Haematol"},{"issue":"4","key":"4780_CR14","first-page":"47","volume":"12","author":"T Pugatsch","year":"1997","unstructured":"Pugatsch T, Or R, Slavin S et al (1997) Amelogenin as marker for bone marrow engraftment: a short term study. J Tumor Marker Oncol 12(4):47\u201351","journal-title":"J Tumor Marker Oncol"},{"key":"4780_CR15","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","volume":"161","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Mul\u00e9 JJ, Spiess PJ et al (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169\u20131188","journal-title":"J Exp Med"},{"key":"4780_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198704093161501","volume":"316","author":"SA Rosenberg","year":"1987","unstructured":"Rosenberg SA et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889\u2013897","journal-title":"N Engl J Med"},{"key":"4780_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000088412","volume":"114","author":"S Slavin","year":"2005","unstructured":"Slavin S (2005) Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation. Acta Haematol 114:214\u2013220","journal-title":"Acta Haematol"},{"key":"4780_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00001622-199104000-00005","volume":"3","author":"S Slavin","year":"1991","unstructured":"Slavin S, Nagler A (1991) New developments in bone marrow transplantation. Curr Opin Oncol 3:254\u2013271","journal-title":"Curr Opin Oncol"},{"key":"4780_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/272624a0","volume":"272","author":"S Slavin","year":"1978","unstructured":"Slavin S, Strober S (1978) Spontaneous murine B-cell leukemia. Nature 272:624\u2013626","journal-title":"Nature"},{"key":"4780_CR20","first-page":"180","volume":"7","author":"S Slavin","year":"1988","unstructured":"Slavin S, Ackerstein A, Weiss L (1988) Adoptive immunotherapy in conjunction with bone marrow transplantation - amplification of natural host defense mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul 7:180\u2013184","journal-title":"Nat Immun Cell Growth Regul"},{"key":"4780_CR21","first-page":"1553","volume":"23","author":"S Slavin","year":"1995","unstructured":"Slavin S, Naparstek E, Nagler A et al (1995) Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553\u20131562","journal-title":"Exp Hematol"},{"issue":"6","key":"4780_CR22","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1182\/blood.V87.6.2195.bloodjournal8762195","volume":"87","author":"S Slavin","year":"1996","unstructured":"Slavin S, Naparstek E, Nagler A et al (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87(6):2195\u20132204","journal-title":"Blood"},{"issue":"10","key":"4780_CR23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00262-010-0878-1","volume":"59","author":"S Slavin","year":"2010","unstructured":"Slavin S, Ackerstein A, Or R et al (2010) Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother 59(10):1511\u20131519","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"4780_CR24","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.bbmt.2017.02.012","volume":"23","author":"T Takahiro","year":"2017","unstructured":"Takahiro T, Fukuda T, Nakashima M et al (2017) Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan marrow donor program. Biol Blood Marrow Transplant 23(6):938\u2013944","journal-title":"Biol Blood Marrow Transplant"},{"key":"4780_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100678","author":"J Tanaka","year":"2020","unstructured":"Tanaka J, Miller JS (2020) Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2020.100678","journal-title":"Blood Rev"},{"key":"4780_CR26","first-page":"196","volume":"23","author":"U Vourka-Karussis","year":"1995","unstructured":"Vourka-Karussis U, Karussis D, Ackerstein A et al (1995) Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL\/J mice. Exp Hematol 23:196\u2013201","journal-title":"Exp Hematol"},{"key":"4780_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/07357909209032785","volume":"10","author":"L Weiss","year":"1992","unstructured":"Weiss L, Reich S, Slavin S (1992) Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 10:19\u201326","journal-title":"Cancer Invest"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04780-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:59:45Z","timestamp":1690477185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4780"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04780-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2606832\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"20 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki, as indicated in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}